Chromium picolinate balances the metabolic and clinical markers in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial
F Kooshki, F Moradi, A Karimi, HR Niazkar… - European Journal of …, 2021 - journals.lww.com
Objective Nonalcoholic fatty liver disease (NAFLD) is a complicated disease and is
considered as a severe global health problem affecting 30% of adults worldwide. The …
considered as a severe global health problem affecting 30% of adults worldwide. The …
Chromium picolinate balances the metabolic and clinical markers in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial
F Kooshki, F Moradi, A Karimi, HR Niazkar… - 2021 - pubmed.ncbi.nlm.nih.gov
Objective Nonalcoholic fatty liver disease (NAFLD) is a complicated disease and is
considered as a severe global health problem affecting 30% of adults worldwide. The …
considered as a severe global health problem affecting 30% of adults worldwide. The …
Chromium picolinate balances the metabolic and clinical markers in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial.
F Kooshki, F Moradi, A Karimi, HR Niazkar… - 2021 - cabidigitallibrary.org
Objective: Nonalcoholic fatty liver disease (NAFLD) is a complicated disease and is
considered as a severe global health problem affecting 30% of adults worldwide. The …
considered as a severe global health problem affecting 30% of adults worldwide. The …
Chromium picolinate balances the metabolic and clinical markers in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial.
F Kooshki, F Moradi, A Karimi, HR Niazkar… - European Journal of …, 2021 - europepmc.org
Objective Nonalcoholic fatty liver disease (NAFLD) is a complicated disease and is
considered as a severe global health problem affecting 30% of adults worldwide. The …
considered as a severe global health problem affecting 30% of adults worldwide. The …
Chromium picolinate balances the metabolic and clinical markers in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial
F Kooshki, F Moradi, A Karimi… - European Journal of …, 2020 - ingentaconnect.com
Objective Nonalcoholic fatty liver disease (NAFLD) is a complicated disease and is
considered as a severe global health problem affecting 30% of adults worldwide. The …
considered as a severe global health problem affecting 30% of adults worldwide. The …